Home › Bladder Cancer › Indiana › Fort Wayne
Bladder Cancer clinical trials in Fort Wayne, IN
4 studies for Bladder Cancer are looking for participants at sites in and around Fort Wayne (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
- Parkview Research Center, Fort Wayne
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY35 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Philadelphia, PA21 studies
- Seattle, WA21 studies
- Edison, NJ21 studies
Other studies in Fort Wayne
- Non-Small Cell Lung Cancer17 studies
- Ovarian Cancer8 studies
- Breast Cancer7 studies
- Chronic Lymphocytic Leukemia7 studies
- Cancer (all types)7 studies
- Lung Cancer6 studies
- Metastatic Cancer6 studies
- Endometrial Cancer5 studies
- Triple-Negative Breast Cancer4 studies
- Multiple Myeloma4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.